Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5R21MH120475 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
Anorexia nervosa (AN) is an eating disorder associated with intense fear of weight gain, food refusal, and severe weight loss. AN has the highest mortality rate among the psychiatric disorders; however, little is known about biomarkers, and no medication has been approved for AN. Many individuals only partially recover, and treatment options, especially for the psychological components of the illness, are not very effective, highlighting the need for more effective treatments.
Brain reward pathways have a direct impact on the drive to eat, and a variety of neuroimaging studies have suggested altered reward processing in AN. The neurotransmitter dopamine has a central role in the reward circuitry to drive food approach, and the dynamic interplay between dopamine receptor response and food restriction could have implications for the pathophysiology of AN. Dopamine-related brain function has been studied indirectly using functional magnetic resonance brain imaging (fMRI) and tasks that deliver reward stimuli unexpectedly, that elicit the so-called prediction error (PE) response.
Research in AN showed repeatedly altered PE processing suggesting altered dopamine circuit function in the disorder.
Dopamine and PE response have also been associated with altered reversal learning, which has important treatment implication for AN as reversal learning is impaired in the disorder and modulation of the dopamine system could improve treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Controls, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine | Experimental | Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Placebo(single dose, 3 hours pre-scan) Scan 2: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 3: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) |
|
| Healthy Controls, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride; | Experimental | Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Placebo(single dose, 3 hours pre-scan) Scan 2: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 3: Amisulpride (single dose, 400 mg, 3 hours pre-scan) |
|
| Healthy Controls, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine | Experimental | Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 2: Placebo(single dose, 3 hours pre-scan) Scan 3: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| amisulpride | Drug | Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI). |
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI). | This task measures responsiveness to unexpected stimulus in the dopamine related brain circuitry. Study participants in both the healthy control group and anorexia nervosa group completed 3 fMRI scans. Prior to each scan subjects were administered one of three study medications (amisulpride, bromocriptine, or placebo). During the fMRI scan, subjects completed a taste reward prediction error task where they viewed visual stimuli and then received one of three conditions: sweet taste, neutral taste, or no solution. 20 percent of stimulus receipt was unexpected, that is there is a mismatch between expectation and outcome. Using a region of interest (ROI)-based approach, brain activation percent signal change values were extracted from the brain images for each subject and compared across groups and medication scans. A repeated measures ANOVA was used to calculate the mean brain activation for each group and each medication scan. | The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days |
| Measurement of Brain Activation (Measured in Percent Signal Change) During Taste Stimulus Expectation Using Functional Magnetic Resonance Imaging (fMRI). | Study participants in both the healthy control group and anorexia nervosa group completed 3 fMRI scans. Prior to each scan subjects were administered one of three study medications (amisulpride, bromocriptine, or placebo). During the fMRI scan, subjects completed a taste reward prediction error task where they viewed visual stimuli and then received one of three conditions: sweet taste, neutral taste, or no solution. Using a region of interest (ROI)-based approach, brain activation percent signal change values were extracted from the brain images for each subject and compared across groups and medication scans. Here only stimulus expectation data were analyzed. A repeated measures ANOVA was used to calculate the mean brain activation for each group and each medication scan. | The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days |
Not provided
Not provided
Inclusion Criteria:
Healthy Controls
Restricting Type Anorexia Nervosa
Exclusion Criteria:
Healthy Controls
Current pregnancy or breast feeding within last 3 months
Illiterate/Blind individuals
First degree relative with current or past eating disorder
Current Medications other than BCP or IUD
Contraindications to amisulpride or bromocriptine (as determined through medical history in bioscreen and PI interview) including: Syncopal migraine; Uncontrolled hypertension; Pheochromocytoma; Prolactinoma; Breast cancer; hypersensitivity/allergy to amisulpride or bromocriptine; History of long QT syndrome; Family history of sudden death or long QT syndrome; History of seizures or seizure disorder
Past or present Axis I psychiatric disorder including substance or alcohol use disorder as determined through SCID-5 clinical interview
Major Medical illness (as determined through medical history in bioscreen and PI interview) such as:
o Conditions that are life threatening: cancer heart disease stroke HIV/AIDS
o Conditions that are life threatening Conditions that cause serious disability without necessarily being life threatening: stroke closed head or spinal cord injuries mental retardation congenital malformations.
o Conditions that cause significant pain or discomfort that can cause serious interruptions to life activities: severe allergies migraine arthritis sickle cell disease
o Conditions that require major commitments of time and effort from care-givers for a substantial period of time: mobility disorders blindness Alzheimer's disease and other dementias chronic obstructive pulmonary disease paraplegia or quadriplegia Down's syndrome depression
o Conditions that may require frequent monitoring: diabetes conditions requiring anticoagulation treatment severe asthma severe allergies schizophrenia and other psychotic illnesses.
o Conditions that predict or are associated with severe consequences: hypertension (associated with heart disease) depression (associated with suicide) diabetes (associated with blindness, kidney failure) alcohol and other substance abuse (associated with intentional and unintentional injuries).
Recent history of suspected substance abuse or a lifetime history of psychostimulant abuse and/or dependence
Metal implants or braces (as determined through fMRI screening form)
Anorexia Nervosa
Pregnancy or breast feeding within last 3 months
Lifetime history of bipolar disorder or psychosis
Illiterate/Blind individuals
Contraindications to amisulpride or bromocriptine (as determined through medical history in bioscreen and PI interview) including: Syncopal migraine; Uncontrolled hypertension; Pheochromocytoma; Prolactinoma; Breast cancer; hypersensitivity/allergy to amisulpride or bromocriptine; History of long QT syndrome; Family history of sudden death or long QT syndrome; History of seizures or seizure disorder
Use of an anti-psychotic or other dopamine acting medication including stimulants within the past week at time of MRI
Recent history of substance abuse or dependence (within the last month)
Major Medical illness (as determined through medical history in bioscreen and PI interview) such as:
o Conditions that are life threatening: cancer heart disease stroke HIV/AIDS
o Conditions that are life threatening Conditions that cause serious disability without necessarily being life threatening: stroke closed head or spinal cord injuries mental retardation congenital malformations.
o Conditions that cause significant pain or discomfort that can cause serious interruptions to life activities: severe allergies migraine arthritis sickle cell disease
o Conditions that require major commitments of time and effort from care-givers for a substantial period of time: mobility disorders blindness Alzheimer's disease and other dementias chronic obstructive pulmonary disease paraplegia or quadriplegia Down's syndrome
o Conditions that may require frequent monitoring: diabetes conditions requiring anticoagulation treatment severe asthma severe allergies schizophrenia and other psychotic illnesses.
o Conditions that predict or are associated with severe consequences: hypertension (associated with heart disease) diabetes (associated with blindness, kidney failure) alcohol and other substance abuse (associated with intentional and unintentional injuries) within the last month
Metal implants or braces (as determined through fMRI screening form)
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Guido Frank, MD | University of California, San Diego | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California San Diego | San Diego | California | 92121 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Of the 31 subjects enrolled, 13 subjects were randomized, 7 participants in the healthy control group and 6 participants in the anorexia nervosa group. Each subject was assigned randomly to one of the 6 study arms. These study arms had different orders of the medication intervention administered at each scan. All subjects received each of the 3 study interventions (amysulpride, bromocriptine, placebo), however, the order of medication intervention at each scan varied based on the randomization.
31 individuals were recruited and enrolled in the study between 10/20/2020 and 6/22/2023 from the San Diego community and the UC San Diego Health Eating Disorders Center for Treatment and Research. Subjects completed several screening processes to determine eligibility and after eligibility was confirmed, were randomly assigned to the study arms. Of those not randomized, 18 individuals were excluded (10 screen failures, 1 voluntary withdrawal by subject, and 7 withdrawals by PI).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Healthy Controls | Subjects at normal weight without psychiatric or eating disorder history |
| FG001 | Anorexia Nervosa | Subjects diagnosed with restricting-type anorexia nervosa according to DSM-V criteria |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1st Intervention (1 Day) |
| ||||||||||||||||||||||
| Washout Period (2-3 Days) |
| ||||||||||||||||||||||
| 2nd Intervention (1 Day) |
| ||||||||||||||||||||||
| Washout Period (2-3 Days) |
| ||||||||||||||||||||||
| 3rd Intervention (1 Day) |
|
Number of baseline participants were the number of subjects who completed all the screening steps and were eligible for the study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Healthy Controls | Subjects at normal weight without psychiatric or eating disorder history |
| BG001 | Anorexia Nervosa | Subjects diagnosed with restricting-type anorexia nervosa according to DSM-V criteria |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI). | This task measures responsiveness to unexpected stimulus in the dopamine related brain circuitry. Study participants in both the healthy control group and anorexia nervosa group completed 3 fMRI scans. Prior to each scan subjects were administered one of three study medications (amisulpride, bromocriptine, or placebo). During the fMRI scan, subjects completed a taste reward prediction error task where they viewed visual stimuli and then received one of three conditions: sweet taste, neutral taste, or no solution. 20 percent of stimulus receipt was unexpected, that is there is a mismatch between expectation and outcome. Using a region of interest (ROI)-based approach, brain activation percent signal change values were extracted from the brain images for each subject and compared across groups and medication scans. A repeated measures ANOVA was used to calculate the mean brain activation for each group and each medication scan. | brain imaging data was pre-processed and brain response was analyzed across groups (healthy control group versus anorexia nervosa group) and within group for each medication. One participant in the anorexia nervosa group had to be excluded from the analysis results due to excessive movement throughout the MRI scan. | Posted | Mean | Standard Error | Percent Signal Change | The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days |
Adverse events were monitored/assessed from the administration of the medication on scan 1 (1st intervention) through the end of scan 3 (3rd intervention). The time period was 9 to 12 days depending on length of each washout period.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Healthy Control Group Placebo Scan | Healthy Control subjects were administered placebo 3 hours prior to the start of the MRI. Subjects performed prediction error and reversal tasks during functional magnetic resonance imaging (fMRI). |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Fatigue | General disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Guido Frank | University of California San Diego | 858-246-2053 | gfrank@health.ucsd.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 12, 2021 | Jan 29, 2025 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Mar 3, 2021 | Jan 29, 2025 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D000856 | Anorexia Nervosa |
| ID | Term |
|---|---|
| D001068 | Feeding and Eating Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077582 | Amisulpride |
| D001971 | Bromocriptine |
| ID | Term |
|---|---|
| D001549 | Benzamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D001565 | Benzoates |
| D000146 |
Not provided
Not provided
There are two groups in this study, healthy controls and anorexia nervosa. Each group completes 3 MRI scans where one of the following medications are administered 3 hours prior to the start of the scan: placebo, amisulpride, bromocriptine. The order of the medication scans was randomized.
Not provided
Not provided
The participant did not know what medication they were receiving on each scan day.
| Healthy Controls, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo | Experimental | Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 2: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 3: Placebo(single dose, 3 hours pre-scan) |
|
| Healthy Controls, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride | Experimental | Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 2: Placebo(single dose, 3 hours pre-scan) Scan 3: Amisulpride (single dose, 400 mg, 3 hours pre-scan) |
|
| Healthy Controls, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo | Experimental | Individuals in the healthy control group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 2: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 3: Placebo(single dose, 3 hours pre-scan) |
|
| Anorexia Nervosa, Scan1: Placebo; Scan2: Amisulpride; Scan3: Bromocriptine | Experimental | Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Placebo(single dose, 3 hours pre-scan) Scan 2: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 3: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) |
|
| Anorexia Nervosa, Scan1: Placebo; Scan2: Bromocriptine; Scan3: Amisulpride; | Experimental | Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Placebo(single dose, 3 hours pre-scan) Scan 2: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 3: Amisulpride (single dose, 400 mg, 3 hours pre-scan) |
|
| Anorexia Nervosa, Scan1: Amisulpride; Scan2: Placebo; Scan3: Bromocriptine | Experimental | Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 2: Placebo(single dose, 3 hours pre-scan) Scan 3: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) |
|
| Anorexia Nervosa, Scan1: Amisulpride; Scan2: Bromocriptine; Scan1: Placebo | Experimental | Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 2: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 3: Placebo(single dose, 3 hours pre-scan) |
|
| Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Placebo; Scan 3: Amisulpride | Experimental | Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 2: Placebo(single dose, 3 hours pre-scan) Scan 3: Amisulpride (single dose, 400 mg, 3 hours pre-scan) |
|
| Anorexia Nervosa, Scan1: Bromocriptine; Scan2: Amisulpride; Scan3: Placebo | Experimental | Individuals in the anorexia nervosa group were randomized to the following scan order. Participants were administered a study medication or placebo 3 hours prior to the start of the scan. The participant did not know what study medication they received for each scan: Scan 1: Bromocriptine (single dose, 1.25 mg, 3 hours pre-scan) Scan 2: Amisulpride (single dose, 400 mg, 3 hours pre-scan) Scan 3: Placebo(single dose, 3 hours pre-scan) |
|
|
| bromocriptine | Drug | Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI). |
|
|
| Placebo | Drug | Placebo pill with no active drug ingredients |
|
| NOT COMPLETED |
|
| 2nd Intervention = Bromocriptine |
|
| 2nd Intervention = Placebo |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| NOT COMPLETED |
|
| 3rd Intervention = Bromocriptine |
|
| 3rd Intervention = Placebo |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | Years |
|
| Sex: Female, Male | All participants were female in this study | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Ethnicity Information | Count of Participants | Participants |
|
| Race (NIH/OMB) | Race information | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Body Mass Index | Mean | Standard Deviation | kg/m^2 |
|
| Eating Disorder Inventory 3 - Drive for Thinness Subscale | The Eating Disorders Inventory (EDI-3) is a 91-question self-report measure that assesses the presence of eating disorders and eating disorder thoughts and behaviors. The drive for thinness subscale on the Eating Disorders Inventory 3 ranges from 0 to 28 with higher scores indicating worse outcome. | Mean | Standard Deviation | units on a scale |
|
| Eating Disorder Inventory 3 - Body Dissatisfaction Subscale | The Eating Disorders Inventory (EDI-3) is a 91-question self-report measure that assesses the presence of eating disorders and eating disorder thoughts and behaviors. The Body Dissatisfaction subscale on the Eating Disorders Inventory 3 ranges from 0 to 40 with higher scores indicating worse outcome. | Mean | Standard Deviation | units on a scale |
|
| Eating Disorders Examination Questionnaire Global Score | The Eating Disorder Examination Questionnaire (EDE-Q) is a 28-item self-report questionnaire, adapted from the semi-structured interview, the Eating Disorder Examination (EDE). The questionnaire is designed to assess the range, frequency and severity of behaviors associated with a diagnosis of an eating disorder. The overall global score ranges from 0 to 6 and is calculated by taking the average of all questions in the measure, with a higher score indicating more problematic eating difficulties. | Mean | Standard Deviation | units on a scale |
|
|
|
|
| Primary | Measurement of Brain Activation (Measured in Percent Signal Change) During Taste Stimulus Expectation Using Functional Magnetic Resonance Imaging (fMRI). | Study participants in both the healthy control group and anorexia nervosa group completed 3 fMRI scans. Prior to each scan subjects were administered one of three study medications (amisulpride, bromocriptine, or placebo). During the fMRI scan, subjects completed a taste reward prediction error task where they viewed visual stimuli and then received one of three conditions: sweet taste, neutral taste, or no solution. Using a region of interest (ROI)-based approach, brain activation percent signal change values were extracted from the brain images for each subject and compared across groups and medication scans. Here only stimulus expectation data were analyzed. A repeated measures ANOVA was used to calculate the mean brain activation for each group and each medication scan. | brain imaging data was pre-processed and brain response was analyzed across groups (healthy control group versus anorexia nervosa group) and within group for each medication | Posted | Mean | Standard Error | Percent Signal Change | The outcome measure was assessed during the taste MRI task on each of the 3 intervention scan days over the course of 9 to 12 days |
|
|
|
| 0 |
| 7 |
| 0 |
| 7 |
| 0 |
| 7 |
| EG001 | Anorexia Nervosa Group Placebo Scan | Anorexia Nervosa subjects were administered placebo pill 3 hours prior to the start of the MRI. Subjects performed prediction error and reversal tasks during functional magnetic resonance imaging (fMRI). | 0 | 6 | 0 | 6 | 0 | 6 |
| EG002 | Healthy Control Group Amisulpride Scan | Healthy Control subjects were administered the dopamine D2 antagonist medication amisulpride 3 hours prior to the start of the MRI. Subjects performed prediction error and reversal tasks during functional magnetic resonance imaging (fMRI). | 0 | 7 | 0 | 7 | 0 | 7 |
| EG003 | Anorexia Nervosa Group Amisulpride Scan | Anorexia Nervosa subjects were administered the dopamine D2 antagonist medication amisulpride 3 hours prior to the start of the MRI. Subjects performed prediction error and reversal tasks during functional magnetic resonance imaging (fMRI). | 0 | 6 | 0 | 6 | 0 | 6 |
| EG004 | Healthy Control Group Bromocriptine Scan | Healthy Control subjects were administered the dopamine D2 receptor agonist medication bromocriptine 3 hours prior to the start of the MRI. Subjects performed prediction error and reversal tasks during functional magnetic resonance imaging (fMRI). | 0 | 7 | 0 | 7 | 2 | 7 |
| EG005 | Anorexia Nervosa Group Bromocriptine Scan | Anorexia Nervosa subjects were administered the dopamine D2 receptor agonist medication bromocriptine 3 hours prior to the start of the MRI. Subjects performed prediction error and reversal tasks during functional magnetic resonance imaging (fMRI). | 0 | 6 | 0 | 6 | 0 | 6 |
| Dizziness | General disorders | Systematic Assessment |
|
Not provided
Not provided
| Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D004879 | Ergotamines |
| D004876 | Ergot Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D004873 | Ergolines |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| Right Ventral Insula Brain Activation |
|
| Left Ventral Striatum Brain Activation |
|
| Right Ventral Striatum Brain Activation |
|
| Left Inferior Orbital Frontal Cortex Brain Activation |
|
| Right Inferior Orbital Frontal Cortex Brain Activation |
|